Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results, Beats Estimates By $0.02 EPS

Protara Therapeutics (NASDAQ:TARA) posted its quarterly earnings data on Friday. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.02, FiscalAI reports.

Protara Therapeutics Trading Up 8.0%

Shares of NASDAQ:TARA traded up $0.17 during trading on Friday, reaching $2.30. 690,546 shares of the stock were exchanged, compared to its average volume of 888,528. The stock has a 50-day moving average price of $3.06 and a 200-day moving average price of $4.51. The firm has a market cap of $135.92 million, a PE ratio of -1.70 and a beta of 1.54. Protara Therapeutics has a 12 month low of $2.09 and a 12 month high of $7.82.

Analysts Set New Price Targets

Several brokerages have issued reports on TARA. Cantor Fitzgerald reiterated an “overweight” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Thursday, October 15th. Finally, Wall Street Zen raised Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 5th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $26.25.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company’s lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer.

Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.